Nitrogen
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Nitrogen: 16q24.1 microdeletion syndrome
One-Sentence Summary
Nitrogen is a medical gas that was originally linked to congenital alveolar capillary dysplasia and persistent fetal circulation syndrome. The TxGNN model predicts it may be effective for 16q24.1 microdeletion syndrome, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | 16q24.1 microdeletion syndrome |
| TxGNN Prediction Score | 0.9973 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 14 of 14) |
| Number of DINs | 14 (marketed: 14) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, nitrogen here most likely refers to a medical gas component (for example in nitric oxide/nitrogen mixtures), so the identity of the drug itself is ambiguous. Its listed uses relate to pulmonary vascular disease in newborns.
16q24.1 microdeletion syndrome involves deletion of the FOXF1 region. This region is also implicated in congenital alveolar capillary dysplasia, so the lung blood vessel and air sac features of the two conditions overlap. This is the main reason the prediction is plausible.
There are limits to this reasoning. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. No trials or publications support it. Any benefit would at most ease pulmonary hypertension symptoms and would not change the underlying genetic disease.
Other top predictions (primary interstitial lung disease specific to childhood at 0.9972, isolated pulmonary capillaritis at 0.9972 and congenital pulmonary lymphangiectasia at 0.9968) are also based on similarities the model learned between related lung diseases, not biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for 16q24.1 microdeletion syndrome.
Canada Market Information
Dosage form and indication text are not listed for these licences. The first 5 of 14 valid licences are shown.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00572829 | NITROGEN 100% | Not listed | Not listed |
| 02297248 | LIQUID NITROGEN NF | Not listed | Not listed |
| 02436590 | LIQUID NITROGEN NF | Not listed | Not listed |
| 02368218 | LIQUID NITROGEN | Not listed | Not listed |
| 02154803 | NITROGEN N.F. | Not listed | Not listed |
Other licences include gaseous nitrogen, medical air, oxygen/nitrogen mixtures and lung diffusion test gas mixtures.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): methemoglobinemia, sulfhemoglobinemia, heart failure.
No drug interaction records were found. Please refer to the package insert for other safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5), with no clinical trials or relevant literature. The drug’s identity and mechanism are unclear, and the only literature found for lower-ranked predictions is off-target keyword matches. The drug is widely marketed in Canada, but only as industrial and medical gases with no indication text.
To proceed, the following is needed:
- Clarify what “nitrogen” refers to here (inert gas, carrier gas, or a nitric oxide/nitrogen mixture).
- Obtain mechanism of action data.
- Obtain Health Canada package insert warnings and contraindications, which are needed before safety screening.
- Search for targeted clinical or case-level evidence in FOXF1-related lung disease.
- Confirm route and dosage form compatibility.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.